CD48 Inhibitors, as conceptualized here, includes a variety of compounds that primarily function as immunosuppressants or immunomodulators. These compounds do not directly target CD48 but can influence its function indirectly by modulating the immune system, particularly T and B cell responses. For example, Cyclosporin A, FK506, and Rapamycin are known for their roles in inhibiting T-cell activation, which is a critical aspect of CD48-mediated immune signaling. By suppressing T-cell activation, these drugs can indirectly impact the function and signaling of CD48.
In addition to these, corticosteroids like Prednisolone and immunosuppressants such as Methotrexate and Azathioprine alter the overall immune response and lymphocyte proliferation. These changes in the immune system can indirectly affect the signaling pathways in which CD48 is involved. Furthermore, drugs like Mycophenolate mofetil, Hydroxychloroquine, and Chloroquine, with their broad immunomodulatory effects, can also potentially influence CD48 function by altering immune cell interactions and responses. The inclusion of Lenalidomide and Thalidomide, known for their immunomodulatory effects, further underscores the approach of indirectly targeting CD48 through modulation of immune responses.